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Objective: In osteoarthritic cartilage, expression of the receptor ALK1 correlates with markers of dele-
terious chondrocyte hypertrophy. Recently, bone morphogenetic protein 9 (BMP9) was identiﬁed as a
high afﬁnity ligand for ALK1. Therefore, we studied if BMP9 signaling results in expression of hyper-
trophy markers in chondrocytes. Furthermore, because transforming growth factorß1 (TGFb1) is a well
known anti-hypertrophic factor, the interaction between BMP9 and TGFb1 signaling was also studied.
Design: Primary chondrocytes were isolated from bovine cartilage and stimulated with BMP9 and/or
TGFb1 to measure intracellular signaling via pSmads with the use of Western blot. Expression of Smad-
responsive genes or hypertrophy-marker genes was measured using qPCR. To conﬁrm observations on
TGFb/Smad3 responsive genes, a Smad3-dependent CAGA12-luc transcriptional reporter assay was per-
formed in the chondrocyte G6 cell line.
Results: In primary chondrocytes, BMP9 potently induced phosphorylation of Smad1/5 and Smad2 to a
lesser extent. BMP9-induced Smad1/5 phosphorylation was rapidly (2 h) reﬂected in gene expression,
whereas Smad2 phosphorylation was not. Remarkably, BMP9 and TGFb1 dose-dependently synergized
on Smad2 phosphorylation, and showed an additive effect on expression of Smad3-dependent genes like
bSerpine1 after 24 h. The activation of the TGFb/Smad3 signaling cascade was conﬁrmed using the
CAGA12-luc transcriptional reporter. BMP9 selectively induced bAlpl and bColX expression, which are
considered early markers of cellular hypertrophy, but this was potently antagonized by addition of a low
dose of TGFb1.
Conclusions: This study shows that in vitro in chondrocytes, BMP9 potently induces pSmad1/5 and a
chondrocyte hypertrophy-like state, which is potently blocked by TGFb1. This observation underlines the
importance of TGFb1 in maintenance of chondrocyte phenotype.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common joint disease, charac-
terized by degeneration of articular cartilage. This loss of articular
cartilage is the result of an imbalance between matrix synthesis
and degradation. Chondrocytes play a crucial role in balancing both
processes with their capacity to produce both matrix molecules,
like collagens, and catabolic proteolytic enzymes such as Matrix. van der Kraan, Experimental
ert Grooteplein 28, 6525 GA,
31-24-3540403.
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ternational. Published by Elsevier LMetalloproteases (MMPs). During OA, a subpopulation of chon-
drocytes differentiates towards a hypertrophy-like phenotype,
characterized by increased production of catabolic enzymes such as
MMP131e3. As a consequence, these chondrocytes actively break
down their surrounding matrix, resulting in pathology.
Signaling by members of the Transforming Growth Factor b
(TGFb)-superfamily, which include TGF-bs, Activins and Bone
morphogenetic proteins (BMPs), regulate matrix synthesis, matrix
degradation and cellular differentiation in chondrocytes4. The
TGFb-superfamily members signal via Activin receptor-Like Kinase
(ALK) receptors5. There are seven ALKs, which phosphorylate spe-
ciﬁc sets of receptor-Smads: ALK1/2/3 and 6 phosphorylate Smad1/
5 (pSmad1/5), whereas ALK4/5 and 7 phosphorylate Smad2/3
(pSmad2/3). Both pSmad2 and pSmad3, but predominantlytd. All rights reserved.
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maintenance of chondrocyte phenotype by potently blocking
hypertrophy6e8, whereas pSmad1 and pSmad5 are required for
chondrocyte hypertrophy and terminal differentiation9e12.
In human osteoarthritic cartilage, ALK1 expression is positively
correlated with expression ofMMP13, the main cartilage degrading
enzyme, and of COL10A1, a marker of chondrocyte terminal differ-
entiation13. Recently, BMP9 was identiﬁed as a high afﬁnity ALK1
ligand14,15. BMP9 is produced in the liver and is present in human,
bovine and murine serum in high amounts of up to 10 ng/ml16e18,
responsible for over 60% of all BMP activity found in serum15. In
endothelial cells, BMP9 potently induces pSmad1/5 and down-
stream signaling14,15. Furthermore, in mesenchymal stem cells,
BMP9 is a potent inducer of chondrocyte hypertrophy, and has been
shown to induce osteogenic differentiation19,20. Combined, these
observations suggest a pro-hypertrophic effect of BMP9 in chon-
drocytes. However, it has been reported that BMP9 is also able to
induce pSmad2 and subsequent downstream effects in endothelial
cells21,22. Furthermore, a synergistic action of BMP9 with TGFb has
been described in endothelial cells, in which BMP9 enhances TGFb
induced Smad2 phosphorylation and Smad3-mediated transcrip-
tional responses23.
In view of the opposing functions of pSmad1/5 and pSmad2/3 in
chondrocyte differentiation, we wondered what the effect of BMP9
signaling on chondrocytes would be. Therefore, the aim of this
study was to investigate BMP9 induced Smad phosphorylation and
downstream gene expression, and to unravel if BMP9 signaling
results in induction of a hypertrophy-like phenotype in chon-
drocytes. Furthermore, because of the reported synergy with TGFb,
we also studied the interaction of BMP9 with TGFb.
We show that in primary chondrocytes, BMP9 indeed induces
both phosphorylation of Smad1/5 and Smad2. Additionally, we
demonstrate that BMP9 can synergize with TGFb on Smad2 phos-
phorylation and expression of certain Smad3-dependent target
genes. Furthermore, we report that BMP9 induces a hypertrophy-
like state in chondrocyte as characterized by Alkaline phosphatase
(Alpl) and Collagen 10a1 (Col10a1) expression, which is potently
counteracted by TGFb1. Our results underline the idea that
pSmad1/5 and pSmad2/3 have opposing roles in regulation of
chondrocyte differentiation.
Materials and methods
Chondrocyte culture
Primary bovine chondrocytes were isolated from the meta-
carpophalangeal joint of cows post mortem. Cartilage slices were
incubated overnight in 1.5 mg/ml Collagenase B (Roche Diagnostics,
Germany) in DMEM/F12 (Gibco, UK) supplied with 50 mg/L
gentamicin (Centrafarm Services, the Netherlands) and 100 mg/L
pyruvate (Gibco UK) in a ratio of 1 g cartilage per 10 ml medium.
Subsequently, chondrocyte suspensionwas spun down at 1500 rpm
for 10min, washed three times using saline (Aguettant, France) and
resuspended in DMEM/F12 containing 10% fetal calf serum (FCS)
(Thermo Scientiﬁc UK). Chondrocytes were seeded at a density of
1  105 cells per cm2 in 6 wells plates (Greiner Bio-one Interna-
tional, the Netherlands) for protein studies, or in 24 wells plates
(Bio-one International, the Netherlands) for mRNA experiments.
Cells were cultured for 1 week at 37C and 5% CO2 before start of
experiments. Subsequently, cells were serum starved and stimu-
lated with recombinant hBMP9, hBMP2, hBMP7 (R&D systems,
USA), or hTGFb1 (BioLegend, the Netherlands) or a combination for
indicated time periods and dosages. Each experiment was con-
ducted at least three times, each time with cells of a different an-
imal. In each experiment, conditions were tested in duplicate.Detection of pSmads using SDS-PAGE and western blot
Cells were placed on ice and washed twice using ice cold saline.
Subsequently, cells were lysed using lysis buffer (Cell signaling,
USA) containing protease inhibitor cocktail (complete, Roche Di-
agnostics, Germany). Cell lysates were sonicated on ice for 10 cy-
cles, of 30 s sonication and 30 s rest, using a Bioruptor (Diagenode,
USA). Hereafter, samples were centrifugated at 4C at 13,500 rpm
for 15 min and pellets were discarded. With a BCA-assay (Thermo
Scientiﬁc, USA), protein concentration was measured. An equal
amount of protein was loaded on a 7.5% Bisacrylamide gel, for SDS-
PAGE. Next, proteins were transferred to a nitrocellulosemembrane
using wet transfer (Towbin buffer, 2.5 h 275 mA at 4C). After
overnight incubation at 4C with 1:1000 polyclonal Rabbit anti P-
Smad1/5 (S463/465)/Smad8 (S426/428) (Cell signaling, USA) or P-
Smad2 (S465/467) (Cell signaling, USA), membranes were incu-
bated with 1:1500 polyclonal Goat anti Rabbit labeled with
Horseradish peroxidase (DAKO, Belgium) for 1 h. Hereafter,
enhanced chemiluminescence (ECL) using ECL plus kit (GE
Healthcare, UK) was used to visualize the proteins. As loading
control b-Actin rabbit mAb (13E5) (Cell signaling) or Gapdh mouse
mAb (1G5) (Sigma Aldrich, Germany) was used, both 1:1500.
Detection of gene expression
RNA was isolated using TRI-reagent (SigmaeAldrich, Germany)
by following manufacturer's protocol. After this procedure, RNA
was dissolved in ultra pure water and RNA concentration was
measured using a NanoDrop photospectrometer (Thermo Scienti-
ﬁc, USA). Subsequently, 1 mg of RNA dissolved in 8 ml water was
treated with 1 ml DNAse (Life Technologies, USA) for 10min at room
temperature, and incubated at 65C with 1 ml 25 mM EDTA (Life
Technologies, USA) for 10 min. To perform reverse transcriptase
(RT) reaction; 1.9 ml ultra purewater, 2.4 ml 10DNAse buffer, 2.0 ml
0.1 M DTT, 0.8 ml 25 mM dNTP, 0.4 mg oligo dT primer, 1 ml 200 U/ml
M-MLV Reverse transcriptase (all Life Technologies, USA) and 0.5 ml
40 U/ml RNAsin (Promega, the Netherlands) was added, and sam-
ples were incubated for 5 min at 25C, 60 min at 39C, and 5 min at
95C using a thermo cycler. Gene expression was measured using
0.5 mM of validated cDNA-speciﬁc primers (see Table I) (Biolegio,
the Netherlands) in a quantitative real time polymerase chain re-
action (qPCR) using SYBR green master mix (Applied Biosystems).
The following protocol was used: after 10 min at 95C, 40 cycles of
15 s 95C and 1 min 60C each were run. For calculations of
the DCt, two reference genes were used: glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and ribosomal protein S14
(RPS14).
CAGA12-luciferase transcriptional reporter assay
The CAGA12-luciferase reporter construct produces luciferase in
response to Smad3-Smad4 activation24. For this assay a human
chondrocyte derived cell line (G6) was used. Cells were transduced
with an adenovirus containing the CAGA12-luciferase construct at a
multiplicity of infection of 10. Two days after transduction, cells
were serum starved for 8 h, and hereafter stimulated with the re-
ported doses of rhTGFb1 and rhBMP9 for 16 h. Subsequently, cells
were lysed using and luciferase activity was measured after adding
Bright glo™ (Promega) on a luminometer according to manufac-
turer's protocol.
Statistics
All quantitative data are expressed as a mean of multiple
repeats ± SD. For every analysis data was checked for normality
Table I
Primer sequences as used in this study
Gene NCBI reference sequence Efﬁciency (%) Forward sequence (50 / 30) Reverse sequence (50 / 30)
bRps14 NM_001077830.2 105 CATCACTGCCCTCCACATCA TTCCAATCCGCCCAATCTTCA
bGapdh NM_001034034.2 100 CACCCACGGCAAGTTCAAC TCTCGCTCCTGGAAGATGGT
bAlk1 NM_001083479.1 99.5 ACAACACAGTGCTGCTCAGACA TGCTCGTGGTAGTGCGTGAT
bAlk2 NM_176663.3 104.8 CGTTGGAGACAGCACTTTAGCA AGAGCCGCTTCCCGATGTA
bSerpine1 NM_174137.2 99 CGAGCCAGGCGGACTTC TGCGACACGTACAGAAACTCTTGA
bSmad7 NM_001192865.1 103 GGGCTTTCAGATTCCCAACTT CTCCCAGTATGCCACCACG
bTgfb1 NM_001166068.1 107 GGTGGAATACGGCAACAAAATCT GCTCGGACGTGTTGAAGAAC
bJunb NM_001075656.1 97.2 CCTTCTACCACGACGACTCA CCGGGTGCTTTGAGATTTCG
bId1 NM_001097568.2 107 GCTCCGCTCAGCACTCTCAA GATCGTCCGCTGGAACACA
bCol10a1 NM_174634.1 92 CCATCCAACACCAAGACACAGT TGCTCTCCTCTCAGTGATACACCTT
bAlpl NM_176858.2 92 CTTTCCCTCCTGGACCAAATTA CCTGGGTCCTTGGAGTGGT
bMmp13 NM_174389.2 92 CTTTCCCTCCTGGACCAAATTA CCTGGGTCCTTGGAGTGGT
bSPP1 NM_174187.2 104.1 ACCCATCTCAGAAGCAGACT TGGGAGGGTATTTTGTTTGTTGT
bCol2a1 NM_001001135.2 97.2 TGATCGAGTACCGGTCACAGAA CCATGGGTGCAATGTCAATG
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(ANOVA) with Tukey's multiple comparison post test was used to
determine the signiﬁcance. The statistical analyses were performed
with the SPSS 20.0 (IBM, Chicago, USA) statistical software package.Results
In primary chondrocytes, BMP9 potently induces pSmad1/5
phosphorylation, and Smad2 phosphorylation to a lesser extent
First, expression of the two receptors BMP9 can use; ALK1 and
ALK215,25 was measured using qPCR, and detected at 0.11 and 0.23
fold of reference gene value respectively. Subsequently, chon-
drocytes were stimulated with a dose range of rhBMP9 to investi-
gate its potency in inducing Smad phosphorylation. Concentrations
reported16e18 as physiological (50 pg, 250 pg, 1 ng, and 2.5 ng/ml)
as well as excessive (25 ng/ml) were tested. In this range, rhBMP9
dose-dependently induced pSmad1/5 after 1 h, starting from a dose
of 50 pg/ml [Fig. 1(A)]. Furthermore, from a dose of 1 ng/ml or
higher, BMP9 also induced pSmad2, but not in all donors. Both
BMP9-induced Smad1/5 and Smad2 phosphorylation lasted up to
at least 2 h after stimulation. Thereforewe conclude that in primary
chondrocytes, BMP9 can induce phosphorylation of both pSmad1/5
and pSmad2, but that the induction of pSmad2 requires a higher
dose of BMP9.Physiological doses of BMP9 induce expression of bId1, a Smad1/5-
dependent gene, but not of Smad3-dependent genes
To investigate if the observed Smad phosphorylation results in
gene transcription, mRNA expression of Smad-dependent genes
was measured 2, 6 and 24 h after stimulation with rhBMP9 using
qPCR [Fig. 1(B)]. The effect of three doses of BMP9 (0.25, 1 and
2.5 ng/ml) with varying induction of Smad phosphorylation, was
measured. Expression of bId1, marker of pSmad1/5 signaling, was
profoundly upregulated ~32 fold (~5 DCt) at all time points
compared to unstimulated samples, but with little difference be-
tween dosage. bSerpine1, a classical Smad3-dependent gene24,26,
was measured to study if BMP9 induced pSmad2 was reﬂected in
gene expression, because in adults not many Smad2-dependent
genes have been identiﬁed26,27, and pSmad2 and pSmad3 follow a
very similar expression pattern, even when induced TGFb inde-
pendently28,29. In contrast to bId1, expression of bSerpine1 was not
induced by BMP9 at any time point. Two other Smad3-dependent
genes; bTgfb126 and bAlk530 were also not affected by BMP9.
Expression of bSmad7 and bJunb, two genes that have been
described as responsive to both pSmad1/5 and pSmad2/331,32 were
upregulated by BMP9, but remarkably only at 1 ng/ml or higher. Inconclusion, BMP9 potently induced expression of Smad1/5-
dependent genes, but not Smad3 speciﬁc genes.BMP9 synergizes with TGFb1 on induction of Smad2
phosphorylation
Because previously a synergistic effect of BMP9 and TGFb1 on
Smad2/3 phosphorylation has been reported23, we investigated if
this synergy also occurs in chondrocytes. To investigate a possible
dose-dependency, two doses of rhTGFb1, 0.1 and 1 ng/ml, and three
doses of BMP9, 0.5, 5 and, based on the previously mentioned
study23, 50 ng/ml were used [Fig. 2(A)]. As expected, stimulation of
chondrocytes with TGFb1 led to phosphorylation of Smad2 and
Smad1/5. Furthermore, BMP9 strongly induced pSmad1/5 but not
pSmad2 in this donor. Most remarkably, BMP9 dose-dependently
enhanced TGFb1-induced Smad2 phosphorylation of both TGFb1
doses. In addition, inhibition of BMP9-induced pSmad1/5 was
observed in the presence of 0.1 ng/ml TGFb1, but not in the pres-
ence of 1 ng/ml TGFb1. These data suggest that TGFb1 and BMP9
synergize on the induction of pSmad2 in chondrocytes.Co-stimulation of chondrocytes with BMP9 and TGFb1 results in an
additive effect on expression of Smad3-dependent genes
To investigate the observed synergy between BMP9 and TGFb1
further downstream,mRNA levels of Smad3-dependent geneswere
measured after 2 and 24 h. A low dose of TGFb1, 0.1 ng/ml, and high
dose of BMP9, 50 ng/ml were used, because these two conditions
showed profound synergy on pSmad2 in the previous experiment.
Two hour after stimulation, both TGFb1 and BMP9 induced
expression of bId1, ~2.8-fold (~1.5 DCt) and ~16-fold (~4 DCt)
respectively, but no additive, synergistic of inhibitory effect, was
observed between both growth factors [Fig. 2(B)]. Expression of the
Smad3-dependent genes bSerpine1, bTgfb1, bAlk5 was not yet
induced by either growth factor alone or in combination. Single
stimulation with TGFb1 or BMP9 both induced bSmad7 expression
~2.5-fold (~1.3 DCt), and co-stimulation increased the expression
~6-fold (~2.5 DCt). Furthermore, bJunb levels were only signiﬁcantly
upregulated ~4-fold (~2 DCt) after co-stimulation with TGFb1 and
BMP9.
Twenty-four hour after stimulation, bId1 expression was still
upregulated ~2.8-fold (~1.5 DCt) by BMP9 but no longer by TGFb1.
Again, no additive, synergistic of inhibitory effect was observed on
this pSmad1/5 dependent gene [Fig. 2(C)]. In contrast to the 2 h
timepoint, Smad3-dependent genes were upregulated after 24 h.
Only co-stimulation with TGFb1 and BMP9 signiﬁcantly upregu-
lated bSerpine1 expression 2-fold (~1 DCt), suggesting enhanced
pSmad2/3 signaling. Enhanced pSmad2/3 signaling is further
Fig. 1. BMP9 induces Smad phosphorylation and downstream gene expression in primary bovine chondrocytes. (A) Primary bovine chondrocytes were stimulated with a dose
range of rhBMP9 for 1 and 2 h, and induction of Smad1/5 and Smad2 phosphorylationwas analyzed onWestern blot using speciﬁc antibodies. pSmad1/5 is potently dose-dependently
induced by BMP9 from 50 pg/ml, whereas pSmad2 is induced from a dose of 1 ng/ml and higher. (B) Chondrocytes of three donors were stimulated in duplo with 0.25,1 and 2.5 ng/ml
BMP9 for 2, 6 and 24 h, to study BMP9-induced gene expression downstreampSmad1/5 and pSmad2/3 using qPCR. BMP9 signiﬁcantly induced expression of bId1 at all time points, but
not of bSerpine1. ForWestern blot, a donor is shown inwhich BMP9-stimulation resulted in both Smad1/5 and Smad2 phosphorylation. For qPCR data, average± S.E.M. was plotted, with
each dot representing the average of one donor. Statistics were calculated using one-way ANOVAwith a Tukey's post-hoc test (* ¼ P < 0.05, ** ¼ P < 0.01 and *** ¼ P < 0.001).
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Fig. 2. BMP9 synergizes with TGFb1 on pSmad2 induction resulting in enhanced expression of pSmad2/3 responsive genes. (A) Chondrocytes were treated for 1 h with either
0.1 or 1 ng/ml of rhTGFb1, 0.5, 5 or 50 ng/ml of rhBMP9 or a combination of both growth factors and subsequently pSmad2 and pSmad1/5 were visualized on Western blot using
speciﬁc antibodies. An inhibitory effect of 0.1 ng/ml on BMP9-induced pSmad1/5 was observed. Furthermore, a synergistic effect of BMP9 on TGFb1 induced pSmad2 was observed,
as signal intensity was increased for co-stimulated samples compared to samples only stimulated with TGFb1. (B) and (C) Co-stimulation of chondrocytes with BMP9 and TGFb1 was
also investigated on gene expression of Smad-dependent genes 2 h (B) or 24 h (C) after stimulation, by stimulating four donors in duplo. At 2 h after stimulation, no effect on
bSerpine1 expression could be detected. bSmad7 and bJunB expression was upregulated more strongly in samples treated with both growth factors compared to single treatment,
however not in a synergistic manner. At 24 h after stimulation, combination treatment induced more bSerpine1, bTgfb1 and bSmad7 expression compared to single treatment. (D) To
study if co stimulation of chondrocytes with BMP9 and TGFb1 results in enhanced Smad responsive biologic activity, the chondrocyte G6 cell line was transduced with the pSmad3-
responsive CAGA12-luc construct, and treated with either 1 ng/ml TGFb1, 5 or 50 ng/ml BMP9 and a combination of both for 16 h. Both growth factors synergized, as co-stimulation
enhanced luciferase production signiﬁcantly compared to TGFb1 stimulation alone. For Western blot, a representative donor is shown. For qPCR data, average ± S.E.M. was plotted
with each dot representing the average of one donor. Statistics were calculated using one-way ANOVA with a Tukey's post-hoc test (* ¼ P < 0.05, ** ¼ P < 0.01 and *** ¼ P < 0.001).
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signiﬁcantly higher expression of this gene compared to single
stimulations; ~3-fold (~1.6 DCt) vs ~2-fold (~1 DCt) respectively.
Similar to 2 h stimulation, an additive effect of TGFb1 and BMP9
was observed on bSmad7; both TGFb1 and BMP9 induced expres-
sion ~2.5-fold (~1.3 DCt), but co-stimulation induced expression
4.6-fold (~2.2 DCt). Therefore, these data show that co-stimulation
with TGFb1 and BMP9 results in an additive effect on pSmad2/3-
responsive gene expression, but not on pSmad1/5-responsive
genes.Synergy between BMP9 and TGFb1 on CAGA12-luc activity
To further conﬁrm the synergy between BMP9 and TGFb1 on
Smad2/3 phosphorylation, we made use of a Smad3/Smad4-
reporter construct: CAGA12-luc. Due to low transfection rates we
were not able to use primary cells and used the human
chondrocyte-like G6 cell line. Stimulation with 1 ng/ml TGFb1
strongly induced luciferase activity ~7-fold, whereas BMP9 in doses
of 5 and 50 ng/ml did not [Fig. 2(D)]. Although co-stimulation of
TGFb1 with 5 ng/ml BMP9 only shows a trend towards enhanced
Fig. 2. (continued).
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and signiﬁcantly enhanced luciferase activity up to ~10-fold, dis-
playing clear synergy between TGFb1 and BMP9, and therefore this
dose was used in our next experiments.
A high dose of BMP2 and BMP7 does not synergize with TGFb1 on
pSmad2 phosphorylation
Now that the synergy between BMP9 and TGFb1 on pSmad2/3
was conﬁrmed in chondrocytes, we investigated if this is a common
BMP characteristic. We compared BMP9 to BMP2 and BMP7 due to
their importance in chondrocyte biology33, and their use of the same
type II receptors but different type I receptors as BMP915,34. Becausethe synergybetweenBMP9andTGFb1 is best observed at a highdose
of BMP9,we chose to use a high dose (250 ng/ml) of BMP2 andBMP7
as well. Both BMPs induced pSmad1/5 comparable to BMP9 (Fig. 3),
but in contrast to BMP9, both BMPs lacked a synergistic interaction
with TGFb1 on pSmad2 phosphorylation. This indicates that the
synergy with TGFb1 on pSmad2 is a unique characteristic of BMP9.
High dose of BMP9 induces expression of chondrocyte hypertrophy
marker genes which is blocked by TGFb1
Overexpression of BMP9's constitutively active receptor ALK1
induces expression of chondrocyte hypertrophy markers13. There-
fore, we analyzed the effect of BMP9 signaling on expression of
Fig. 3. BMP2 and BMP7 do not synergize with TGFb1 on pSmad2. Chondrocytes
were treated for 1 h with 250 ng/ml of BMP2 or 250 ng/ml BMP7, 50 ng/ml BMP9 and
0.1 ng/ml TGFb, and pSmad1/5 and pSmad2 induction was analyzed on Western blot
using speciﬁc antibodies. Although both BMPs induced similar pSmad1/5 compared to
BMP9, BMP2 and BMP7, unlike BMP9, did not synergize with TGFb1 on induction of
Smad2 phosphorylation. This Western blot depicts a representative experiment.
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potent blocker of chondrocyte hypertrophy, co-stimulation with
TGFb1 was included (Fig. 4). After 1 week, bId1 expression was
highly upregulated ~49-fold (~5.6 DCt) by 25 ng/ml BMP9.
Remarkably, co-stimulation with 0.1 ng/ml TGFb1 signiﬁcantly
lowered this induction to ~21-fold (~4.4 DCt). Of the four markers of
chondrocyte hypertrophy that were measured, expression of
bMMP13 or bSPP1 was not signiﬁcantly regulated by BMP9, TGFb1,
or the combination of both. In contrast, expression of both bAlpl and
bCol10a1, was highly upregulated by 25 ng/ml BMP9; ~10.6-fold
(~3.4 DCt) and ~4.6-fold (~2.2 DCt) respectively. Strikingly, 0.1 ng/
ml TGFb1 could block BMP9-induced expression of these hyper-
trophy markers. Notably, matrix mineralization could not yet be
observed by either alcian blue or alizarin red staining in our ex-
periments. However, also after addition of two known inducers of
matrix mineralization; b-glycerophosphate and ascorbic acid, no
mineralization could be observed either. Apart from the inhibition
of hypertrophy marker genes, co-stimulation also signiﬁcantly
induced bCol2a1 expression ~2.1-fold (~1.1 DCt), showing a bene-
ﬁcial effect of simultaneous stimulation with TGFb1 and BMP9 on
matrix production. Based upon these results we conclude that
BMP9 induces the expression of certain hypertrophy-like marker
genes, which is counteracted by a low dose of TGFb1.Discussion
Increasing evidence suggests pivotal, but opposing, roles for
pSmad2/3 and pSmad1/5 in chondrocyte differentiation, with a
hypertrophy-inducing role for the latter35e37. We investigated
in vitro in primary chondrocytes the effects of BMP9, a potent
pSmad1/5 inducing ligand that circulates in blood. We report that,
in primary chondrocytes, BMP9 induces pSmad1/5 and expression
of the chondrocyte hypertrophy markers bCol10a1 and bAlpl, but
that this effect is potently counteracted by TGFb1. Possibly, this
inhibition is facilitated by the synergy we observed between BMP9
and TGFb1 on Smad2/3 phosphorylation, a synergy which is unique
for BMP9 compared to BMP2 or BMP7.Previous reports have characterized BMP9 as a potent inducer of
pSmad1/5 in a variety of endothelial cell lines21,22. We were able to
show that also in primary chondrocytes, BMP9 potently induces
pSmad1/5. Surprisingly, in some donors, we not only observed
Smad1/5 but also Smad2 phosphorylation after stimulation with
BMP9. In some, but not all, endothelial cell lines, BMP9-induced
pSmad2 has been reported as well21,22. BMP9-induced pSmad2 is
remarkable, as both type I receptors that BMP9 can bind; ALK1 and
ALK2, are not known to directly phosphorylate Smad2. Therefore,
how BMP9 induces pSmad2 is yet unclear.
After phosphorylation, Smad1/5 and Smad2/3 form complexes
with Smad4, the common-Smad, and translocate to the nucleus
where these complexes bind DNA and regulate gene transcription5.
When analyzing BMP9-induced gene expression in primary chon-
drocytes,weobserved rapid and robust up regulationof the pSmad1/
5-dependent gene bId1, but not of pSmad3-dependent genes like
bSerpine1. This lack of Smad3-dependent gene expression is appar-
ently in contradictionwith our observations onWestern blot, which
suggest pSmad2/3 signaling. However, in both endothelial cells and
chondrocytes, inhibition of pSmad3 signaling by ALK1 signaling has
previously been reported. In both cell types, over-expression of
constitutively active ALK1 reduced pSmad3-dependent transcrip-
tional activity, while not affecting Smad phosphorylation itself38e40.
Possibly, the rapid induction of Smad7 we found in this study can
explain the observed lack of pSmad2/3-responsive gene expression.
Smad7 is an inhibitor of receptor-Smad signaling (inhibitory-Smad)
withamultitudeof actions, including theability toprevent bindingof
the pSmad2/3-Smad4 complex to DNA41,42. Expression of this
inhibitory-Smad was rapidly induced ~3.2-fold within 2 h of BMP9
stimulation. Additionally, in chondrocytes, adenoviral over-
expression of Smad7 has previously been reported to inhibit mSer-
pine1 transcription43. Therefore, in primary chondrocytes, Smad7
might be an important regulator of the crosstalk between the BMP9-
induced pSmad1/5 and pSmad2/3 signaling pathways.
The crosstalk between pSmad1/5 and pSmad2/3 signaling con-
trols chondrocyte differentiation (reviewed in37). Via an interaction
with the Runx2, a transcription factor regarded as the key regulator
of endochondral ossiﬁcation, pSmad1 and 5 can directly enhance
terminal differentiation by inducing expression of genes like
Col10a1 and Mmp1335,44,45. Prolonged stimulation with BMP9
indeed induced expression of the early hypertrophy marker genes
bCol10a1 and bAlpl, but increased bMmp13 expression was not
observed. However, bMmp13 expression mainly occurs in late stage
hypertrophic chondrocytes46, a cellular state most likely not ach-
ieved in our experimental setting, also indicated by the lack of
mineralization in our experiments. Compared to pSmad1/5,
pSmad2/3 has an opposite effect on Runx2 activity; it silences
Runx2-responsive genes via recruitment of histone deacetylases36.
In our experiments, BMP9-induced expression of hypertrophy
markers was indeed antagonized by a low dose of TGFb1, a well
known inducer of Smad2 and 3 phosphorylation. Possibly, this
antagonism is facilitated by the synergy we observed between
BMP9 and TGFb1 on Smad2/3 phosphorylation. In addition to Smad
signaling, Smad-independent BMP-signaling via e.g., ERK and TAK1
can play a role in chondrocyte hypertrophy47,48. A limitation of our
study is that we did not investigate these pathways. However, the
Smad-dependent and Smad-independent pathways are closely
interwoven by regulation of the former by the latter49, and we
think that Smad signaling is the key effector in BMP-induced
chondrocyte hypertrophy. Nonetheless, additional experiments
are needed to reveal whether this actually holds true.
In cartilage, the inhibition of BMP9 induced hypertrophy is
possibly an important physiological role of TGFb1. TGFb1 itself is
produced by chondrocytes, and present in cartilage in high
amounts50. Although we were unable to detect BMP9 mRNA in
Fig. 4. BMP9 induces expression of early hypertrophy-like marker genes, which is potently blocked by a low dose of TGFb1. Chondrocytes of three donors were treated in
duplo with 0.1 ng/ml of rhTGFb1, 5 or 50 ng/ml of rhBMP9 or a combination of both growth factors for 7 days, and gene expression of markers of chondrocyte hypertrophy and
terminal differentiation were measured using qPCR. Stimulation medium was refreshed every 3 days. After 7 days of treatment, expression of both Col10a1 and bAlpl was
signiﬁcantly increased in samples stimulated with 50 ng/ml rhBMP9, but not in samples treated with 50 ng/ml rhBMP9 and 0.1 ng/ml TGFb1, indicating an inhibitory effect of TGFb1.
This inhibitory effect of TGFb1 on BMP9 induced signaling is reﬂected in bId1 expression, as addition of TGFb1 inhibited BMP9 induced bId1 expression signiﬁcantly. For qPCR data,
average ± S.E.M. was plotted with each dot representing the average of one donor. Statistics were calculated using one-way ANOVA with a Tukey's post-hoc test.
A. van Caam et al. / Osteoarthritis and Cartilage 23 (2015) 985e995992chondrocytes, BMP9 is most likely readily available in cartilage
in vivo. The liver produces large amounts of BMP9, and BMP9 cir-
culates in levels as high as ~10 ng/ml in bovine and ~12 ng/ml in
human serum and plasma16e18. Furthermore, BMP9 is responsible
for over 60% of all BMP activity in serum, indicating BMP9's relative
abundance15. Because synovial ﬂuid partly consists of plasmaﬁltrate51, it is likely that chondrocytes are constantly exposed to
BMP9 via synovial ﬂuid, but this still has to be conﬁrmed. Consid-
ering that BMP9 signaling can induce hypertrophy, inhibition of
this signal would be of crucial importance for the maintenance of
articular cartilage, and therefore an important role of TGFb1.
Additional in vivo experiments are needed to test this hypothesis. In
A. van Caam et al. / Osteoarthritis and Cartilage 23 (2015) 985e995 993a pilot study, we tried to investigate to ability of BMP9 to induce
cartilage hypertrophy in vivo by intra-articular injection of BMP9,
but severe osteophyte formation, resulting in disrupted joint ho-
meostasis, in response to BMP9 made it very difﬁcult to draw
conclusions on BMP9's direct effect on cartilage.
BMP9 levels are not known to correlate with OA, but its serum
level doesn't decrease during aging in mice18. We think that this
stable level of BMP9 becomes a problem for cartilage during aging,
in view of age-related loss of TGFb signaling11,13. From cartilage-
speciﬁc TGFb-receptor type 2 knockout mice it is known that
mice lacking TGFb-signaling develop increased cartilage degrada-
tion and expression of hypertrophy markers52. It would be very
interesting to see if BMP9 is the driving force behind this process by
crossing these mice with BMP9 knockout mice.
How BMP9 and TGFb1 can synergize on pSmad2/3 phosphory-
lation and downstream gene expression is yet unknown. However,
the synergy between both growth factors can be observed rapidly,
which suggests a mechanism upstream in the signaling pathway.
TGFb-superfamily signaling requires formation of a hetero-
tetrameric receptor complex containing two type II and two type I
receptors, inwhich receptor-Smads are phosphorylated by the type
I receptors5. TGFb1 can bind two type I receptors, ALK1 and ALK5,
and form complexes containing both. Furthermore, complex for-
mation between ALK1 and ALK5 induces both pSmad1/5 and
pSmad2/339. Putatively, a receptor-complex containing both ALK1
and ALK5 can phosphorylate less Smad2/3 compared to a complex
containing ALK5 twice because ALK1 cannot phosphorylate
pSmad2/3. Using radiolabeled ligands, it has been shown that
BMP9 has a far greater afﬁnity for ALK1 than TGFb115. Possibly,
BMP9 affects TGFb1-induced receptor complex formation by
sequestering ALK1, forcing TGFb1 to signal via receptor complexes
containing solely ALK5, thus resulting in more pSmad2. This idea is
supported by the observation that two other BMPs, BMP2 and
BMP7, do not synergize with TGFb1 on pSmad2 even at a very high
dosage. These BMPs share the induction of pSmad1/5 and the use of
type II receptors like BMPR2 with BMP9, but do not use ALK1,
making it more likely that ALK1 is involved in the synergy between
BMP9 and TGFb1. Moreover, the synergy between TGFb1 and BMP9
is most obvious at high levels of BMP9, which would sequester
ALK1 more efﬁciently.
In summary, this study shows that in chondrocytes, the ALK1-
ligand BMP9 induces pSmad1/5 and downstream gene expres-
sion, leading within a week to a hypertrophy-like state in chon-
drocytes characterized by bAlpl and bColX expression. However, we
also show that this can potently be inhibited by addition of a low
dose of TGFb1. Possibly, the observed synergy between BMP9 and
TGFb1 on Smad2 phosphorylation plays a role in this inhibitory
effect. Although we only investigated this interaction in vitro, we
propose that the interaction of BMP9 with TGFb1 underlines the
importance of TGFb1 in maintenance of chondrocyte phenotype
and furthermore that our observations support the idea that
pSmad1/5 and pSmad2/3 have opposing roles in regulation of
chondrocyte differentiation.
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